In the aftermath of the trading day, the price slide that started in the afternoon increased to over 16 percent. At first, the reason was not quite obvious.
In the morning, the imminent release of the vaccine for children from the age of twelve in the USA had set a new record high. Biontech boss Ugur Sahin also said at an event by the Wall Street Journal on Tuesday that, according to him, the pandemic would last until mid-2022. Some investors might have hoped for more pointed statements about the need for recurring booster vaccinations. Biontech's share price had doubled again since the end of March, and even quintupled since the beginning of the pandemic.